---
title: Combination Therapy for Neovascular Age Related Macular Degeneration
nct_id: NCT00447031
overall_status: WITHDRAWN
phase: NA
sponsor: Yonsei University
study_type: INTERVENTIONAL
primary_condition: Macular Degeneration
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00447031.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00447031"
ct_last_update_post_date: 2010-02-09
last_seen_at: "2026-05-12T07:10:33.413Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Combination Therapy for Neovascular Age Related Macular Degeneration

**Official Title:** Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone Acetonide Injection Versus Intravitreal Bevacizumab for Age Related Macular Degeneration

**NCT ID:** [NCT00447031](https://clinicaltrials.gov/study/NCT00447031)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Insufficient patients who met inclusion criteria
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** Yonsei University
- **Conditions:** Macular Degeneration
- **Start Date:** 2007-03
- **Completion Date:** 2007-11
- **CT.gov Last Update:** 2010-02-09

## Brief Summary

Exudative age related macular degeneration (ARMD) is most common cause of blindness in old population. It is clear that no single therapy addresses the multifactorial pathogenesis of the disease. Recently, studies of intravitreal anti-VEGF therapies such as pegaptanib and bevacizumab have shown the beneficial effect in visual acuity in the treatment of neovascular ARMD. However, the problem with these intravitreal injections is that therapy must be frequently administered for a prolonged but unknown period of time to maintain the benefit. Prolonged, frequent injections may be associated with additional safety risk,lack of convenience and high treatment cost.

Intravitreal steroid injection with anti-inflammatory properties limits any further VEGF upregulation initiated by the inflammation which has been known as one of the pathogenesis and causes of recurrence after the treatment of the neovascular ARMD.

The researchers hypothesize that the combined treatment of intravitreal bevacizumab and triamcinolone acetonide may decrease the recurrence rate after the treatment and obviate the frequent intravitreal injections in the treatment of neovascular ARMD.

In this study, the researchers will compare the recurrence rate of combined treatment of intravitreal bevacizumab and triamcinolone acetonide versus intravitreal bevacizumab alone in the treatment of neovascular ARMD.

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Neovascular ARMD confirmed with 90+ noncontact lens biomicroscopy, fluorescein angiography, ocular coherence tomography

Exclusion Criteria:

* Intractable systemic hypertension
* Recent myocardial infarct within 6 months at enrollment
* Recent cerebrovascular attack within 6 months
```

## Interventions

- **intravitreal bevacizumab and triamcinolone acetonide** (DRUG)

## Primary Outcomes

- **recurrence rate**
- **best corrected visual acuity**

## Secondary Outcomes

- **complication rate**

## Locations (1)

- Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `status.whyStopped` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of ophthalmology, yonsei university college of medicine|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00447031.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00447031*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*